Homepage > Company > Media > Pharma News > 2018 > Cadila Healthcare Ltd's subsidiary gets 5 observations from US FDA for its facility

Cadila Healthcare Ltd's subsidiary gets 5 observations from US FDA for its facility

The USFDA inspected the injectables manufacturing facility of Liva Pharmaceuticals Ltd. (Liva) which is located at Vadodara, from 20th August 2018 to 28th August 2018. Liva is a 100% subsidiary of Cadila Healthcare Ltd.

This was a product specific Pre Approval Inspection. The inspection concluded with 5 observations. Liva will respond to the USFDA within 15 days. It may be noted that at present Liva does not export any products to the US market.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.396.45 as compared to the previous close of Rs. 396.35. The total number of shares traded during the day was 143692 in over 2108 trades.

The stock hit an intraday high of Rs. 401.85 and intraday low of 393.65. The net turnover during the day was Rs. 57197497.

2018-08-29

http://equitybulls.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)